Cargando…
Acquired thrombotic thrombocytopenic purpura with isolated CFHR3/1 deletion—rapid remission following complement blockade
BACKGROUND: Thrombotic thrombocytopenic purpura (TTP) is caused by the abundance of uncleaved ultralarge von Willebrand factor multimers (ULvWF) due to acquired (autoantibody-mediated) or congenital vWF protease ADAMTS13 deficiency. Current treatment recommendations include plasma exchange therapy a...
Autores principales: | Bitzan, Martin, Hammad, Rawan M., Bonnefoy, Arnaud, Al Dhaheri, Watfa Shahwan, Vézina, Catherine, Rivard, Georges-Étienne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6019431/ https://www.ncbi.nlm.nih.gov/pubmed/29728803 http://dx.doi.org/10.1007/s00467-018-3957-8 |
Ejemplares similares
-
Complement and cytokine response in acute Thrombotic Thrombocytopenic Purpura
por: Westwood, John-Paul, et al.
Publicado: (2014) -
Thrombotic thrombocytopenic purpura
por: Knöbl, Paul
Publicado: (2018) -
Complement Inhibition in the Treatment of SLE-Associated Thrombotic Thrombocytopenic Purpura
por: Boneparth, Alexis, et al.
Publicado: (2015) -
Caplacizumab use for immune thrombotic thrombocytopenic purpura: the Milan thrombotic thrombocytopenic purpura registry
por: Agosti, Pasquale, et al.
Publicado: (2023) -
Thrombotic Thrombocytopenic Purpura and Gemcitabine
por: Kasi, Pashtoon Murtaza
Publicado: (2011)